person · Reporting owner

Morrison Briggs

Disclosed activity across 9 companies

Tapewire entity: 35090
SEC CIK: 0001654430

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ARVINAS, INC.ARVN · Entity 5355	Director	June 24, 2026	June 26, 2026
CRISPR Therapeutics AGCRSP · Entity 3852	Director	June 05, 2026	June 09, 2026
Carisma Therapeutics Inc.CARM · Entity 74418	Director	June 26, 2024	June 27, 2024
Codiak BioSciences, Inc.CDAK · Entity 114958	Director	February 17, 2021	February 17, 2021
NextCure, Inc.NXTC · Entity 7461	Director	June 11, 2020	June 15, 2020
Oncorus, Inc.ONCR · Entity 112213	Director	October 01, 2020	October 01, 2020
Repare Therapeutics Inc.RPTX · Entity 68433	Director	June 17, 2024	June 20, 2024
Syndax Pharmaceuticals IncSNDX · Entity 4578	Director	February 07, 2024	February 09, 2024
Werewolf Therapeutics, Inc.HOWL · Entity 7244	Director	June 12, 2025	June 13, 2025

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ARVINAS, INC.

Report date June 24, 2026 · Filed June 26, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	111,548	Reported balance After 2026-06-24 transaction · row 1 1 source row Row 1 · 2026-06-24 · Grant · Acquired 15,527 · Balance 111,548 F1: The restricted stock units (each, an "RSU") were granted by the Issuer on June 24, 2026 and each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration. The RSUs shall vest in full on the earlier of (i) June 24, 2027 or (ii) immediately prior to the first annual meeting of stockholders occurring after the date of grant, subject to the reporting person's continued service with the Issuer on the vesting date.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.05 · Expires 2036-06-23	Direct	22,714	Reported balance After 2026-06-24 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-24 · Grant · Acquired 22,714 · Balance 22,714 F2: This option award was granted on June 24, 2026. The shares underlying the award shall vest in full on the earlier of (i) June 24, 2027 or (ii) immediately prior to the first annual meeting of stockholders occurring after the date of grant, subject to the reporting person's continued service with the Issuer on the vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The restricted stock units (each, an "RSU") were granted by the Issuer on June 24, 2026 and each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration. The RSUs shall vest in full on the earlier of (i) June 24, 2027 or (ii) immediately prior to the first annual meeting of stockholders occurring after the date of grant, subject to the reporting person's continued service with the Issuer on the vesting date.

F2: This option award was granted on June 24, 2026. The shares underlying the award shall vest in full on the earlier of (i) June 24, 2027 or (ii) immediately prior to the first annual meeting of stockholders occurring after the date of grant, subject to the reporting person's continued service with the Issuer on the vesting date.

CRISPR Therapeutics AG

Report date June 05, 2026 · Filed June 09, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $51.84 · Expires 2036-06-05	Direct	13,000	Reported balance After 2026-06-05 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-05 · Grant · Acquired 13,000 · Balance 13,000 F1: Subject to continued service to the Company or any of its subsidiaries, the options will vest and become exercisable in 12 equal monthly installments on the final day of each succeeding calendar month occurring after the grant date provided that the first installment vests on June 30, 2026 and the last installment vests on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2027 Annual Meeting.

Filing footnotes · ownership attribution and instrument terms

F1: Subject to continued service to the Company or any of its subsidiaries, the options will vest and become exercisable in 12 equal monthly installments on the final day of each succeeding calendar month occurring after the grant date provided that the first installment vests on June 30, 2026 and the last installment vests on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2027 Annual Meeting.

Carisma Therapeutics Inc.

Report date June 26, 2024 · Filed June 27, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.22 · Expires 2034-06-26	Direct	19,350	Reported balance After 2024-06-26 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2024-06-26 · Grant · Acquired 19,350 · Balance 19,350 F1: The shares underlying this option vest with respect to all of the shares underlying such option on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to the non-employee director's continued service as a director.

Filing footnotes · ownership attribution and instrument terms

F1: The shares underlying this option vest with respect to all of the shares underlying such option on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to the non-employee director's continued service as a director.

Codiak BioSciences, Inc.

Report date February 17, 2021 · Filed February 17, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	4,761	Reported balance After 2021-02-17 transaction · row 1 1 source row Row 1 · 2021-02-17 · Purchase · Acquired 4,761 · Balance 4,761

NextCure, Inc.

Report date June 11, 2020 · Filed June 15, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.13 · Expires 2030-06-10	Direct	14,250	Reported balance After 2020-06-11 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2020-06-11 · Grant · Acquired 14,250 · Balance 14,250 F1: The option vests in full on the earlier of June 11, 2021 and the date of the 2021 Annual Meeting of Stockholders.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests in full on the earlier of June 11, 2021 and the date of the 2021 Annual Meeting of Stockholders.

Oncorus, Inc.

Report date October 01, 2020 · Filed October 01, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.57 · Expires 2026-04-26	Direct	Not disclosed	Reported balance Holding disclosure · report date 2020-10-01 · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · Balance Not disclosed F1: Fully vested.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.57 · Expires 2026-08-28	Direct	Not disclosed	Reported balance Holding disclosure · report date 2020-10-01 · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · Balance Not disclosed F1: Fully vested.

Filing footnotes · ownership attribution and instrument terms

F1: Fully vested.

Repare Therapeutics Inc.

Report date June 17, 2024 · Filed June 20, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.80 · Expires 2034-06-16	Direct	27,200	Reported balance After 2024-06-17 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2024-06-17 · Grant · Acquired 27,200 · Balance 27,200 F1: The option will vest in equal monthly installments over twelve (12) months from the date of grant, subject to Reporting Person continuing to provide service through each such date.

Filing footnotes · ownership attribution and instrument terms

F1: The option will vest in equal monthly installments over twelve (12) months from the date of grant, subject to Reporting Person continuing to provide service through each such date.

Syndax Pharmaceuticals Inc

Report date February 07, 2024 · Filed February 09, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	34,836	Reported balance After 2024-02-07 transaction · row 1 1 source row Row 1 · 2024-02-07 · Grant · Acquired 17,000 · Balance 34,836 F1: Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control.

Filing footnotes · ownership attribution and instrument terms

F1: Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control.

Werewolf Therapeutics, Inc.

Report date June 12, 2025 · Filed June 13, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.29 · Expires 2035-06-11	Direct	27,000	Reported balance After 2025-06-12 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2025-06-12 · Grant · Acquired 27,000 · Balance 27,000 F1: The option was granted on June 12, 2025. The shares underlying the option vest in full on the earlier of the first anniversary of the grant date and the next annual meeting of stockholders following the grant date, subject to the reporting person's continued service as a director.

Filing footnotes · ownership attribution and instrument terms

F1: The option was granted on June 12, 2025. The shares underlying the option vest in full on the earlier of the first anniversary of the grant date and the next annual meeting of stockholders following the grant date, subject to the reporting person's continued service as a director.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
September 20, 2021 Filed Sep 21, 2021 20:35 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	SaleCommon Stock	50	$20.00	$1,000.00	Disclosure SEC source: 0001562180-21-006038 · primarydocument.xml · nonDerivative · entry 4 Morrison Briggs · CIK 0001654430 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,336 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Read SEC document
September 20, 2021 Filed Sep 21, 2021 20:35 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	Exercise / conversionCommon Stock	50	$7.20	$360.00	Disclosure SEC source: 0001562180-21-006038 · primarydocument.xml · nonDerivative · entry 3 Morrison Briggs · CIK 0001654430 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,386 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
September 17, 2021 Filed Sep 21, 2021 20:35 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	Exercise / conversionStock Options (Right to buy) · Derivative	70,262	$0.00 Strike: $7.20	$0.00	Disclosure SEC source: 0001562180-21-006038 · primarydocument.xml · derivative · entry 5 Morrison Briggs · CIK 0001654430 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 70,262 shares Expires 2025-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option is fully vested. Read SEC document
September 17, 2021 Filed Sep 21, 2021 20:35 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	SaleCommon Stock	70,262	$20.07	$1,410,017.82	Disclosure SEC source: 0001562180-21-006038 · primarydocument.xml · nonDerivative · entry 2 Morrison Briggs · CIK 0001654430 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,336 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. F2 · price: The sale prices ranged from $20.00 to $20.32. Read SEC document
September 17, 2021 Filed Sep 21, 2021 20:35 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	Exercise / conversionCommon Stock	70,262	$7.20	$505,886.40	Disclosure SEC source: 0001562180-21-006038 · primarydocument.xml · nonDerivative · entry 1 Morrison Briggs · CIK 0001654430 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,598 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 08, 2021 Filed Jun 11, 2021 00:00 UTC	ARVINAS, INC. ARVN · Entity 5355	GrantStock Option (right to buy) · Derivative	7,511	$0.00 Strike: $78.53	$0.00	Disclosure SEC source: 0001209191-21-039675 · doc4.xml · derivative · entry 1 Morrison Briggs · CIK 0001654430 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,511 Underlying: Common Stock · 7,511 shares Expires 2021-06-07 F1 · derivative.exercise_date: This option award was granted on June 8, 2021. The shares underlying the award shall vest in full on June 8, 2022 or, if earlier, the date of the first meeting of the board of directors of the Issuer held after the Issuer's next annual meeting of stockholders. Read SEC document
May 13, 2021 Filed May 14, 2021 20:53 UTC	Repare Therapeutics Inc. RPTX · Entity 68433	GrantStock Option (right to buy) · Derivative	21,000	$0.00 Strike: $32.44	$0.00	Disclosure SEC source: 0001209191-21-032780 · doc4.xml · derivative · entry 1 Morrison Briggs · CIK 0001654430 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 21,000 shares Expires 2031-05-13 F1 · derivative.exercise_date: The option will vest in equal monthly installments over twelve (12) months from the date of grant, subject to Reporting Person continuing to provide service through each such date. Read SEC document
April 30, 2021 Filed May 4, 2021 20:30 UTC	Werewolf Therapeutics, Inc. HOWL · Entity 7244	GrantStock Option (right to buy) · Derivative	23,200	$0.00 Strike: $16.00	$0.00	Disclosure SEC source: 0000899243-21-018110 · doc4.xml · derivative · entry 1 Morrison Briggs · CIK 0001654430 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,200 Underlying: Common Stock · 23,200 shares Expires 2031-04-29 F1 · derivative.exercise_date: The option was granted on April 30, 2021. The shares underlying the option vest over three years, with one-third of the shares vesting on the first anniversary of the date of grant and the remaining shares vesting in equal monthly installments thereafter. Read SEC document
February 17, 2021 Filed Feb 17, 2021 23:05 UTC	Codiak BioSciences, Inc. CDAK · Entity 114958	PurchaseCommon Stock	4,761	$21.00	$99,981.00	Disclosure SEC source: 0000899243-21-006954 · doc4.xml · nonDerivative · entry 1 Morrison Briggs · CIK 0001654430 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,761 Read SEC document
February 08, 2021 Filed Feb 10, 2021 21:23 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	Exercise / conversionStock Options (Right to buy) · Derivative	35,156	$0.00 Strike: $7.20	$0.00	Disclosure SEC source: 0001562180-21-001044 · primarydocument.xml · derivative · entry 3 Morrison Briggs · CIK 0001654430 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,156 shares Expires 2025-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option is fully vested. Read SEC document
February 08, 2021 Filed Feb 10, 2021 21:23 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	SaleCommon Stock	35,156	$20.55	$722,403.07	Disclosure SEC source: 0001562180-21-001044 · primarydocument.xml · nonDerivative · entry 2 Morrison Briggs · CIK 0001654430 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,336 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule10b5-1 plan adopted by the Reporting Person. Following the sale reported in this Form 4, the Reporting Person has a total of 1,161,507 options to purchase shares of common stock that are vested and immediately exercisable and a total of 518,334 options to purchase shares of common stock that have not yet vested. F2 · price: The sale prices ranged from $20.00 to $20.93. Read SEC document
February 08, 2021 Filed Feb 10, 2021 21:23 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	Exercise / conversionCommon Stock	35,156	$7.20	$253,123.20	Disclosure SEC source: 0001562180-21-001044 · primarydocument.xml · nonDerivative · entry 1 Morrison Briggs · CIK 0001654430 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,492 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 03, 2021 Filed Feb 5, 2021 21:21 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	GrantStock Option (Right to Buy) · Derivative	195,000	$0.00 Strike: $21.36	$0.00	Disclosure SEC source: 0001562180-21-000932 · primarydocument.xml · derivative · entry 2 Morrison Briggs · CIK 0001654430 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,000 Underlying: Common Stock · 195,000 shares Expires 2031-02-03 F2 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest monthly over a four-year period. Read SEC document
January 31, 2021 Filed Feb 5, 2021 21:21 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	OtherCommon Stock	1,771	$12.00	$21,252.00	Disclosure SEC source: 0001562180-21-000932 · primarydocument.xml · nonDerivative · entry 1 Morrison Briggs · CIK 0001654430 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,336 F1 · kind: The Reporting Person is voluntarily filing this Form 4 to report the acquisition of 1,771 shares by the Reporting Person on 01/31/2021 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document
November 10, 2020 Filed Nov 12, 2020 22:55 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	Exercise / conversionStock Options (Right to buy) · Derivative	17,466	$0.00 Strike: $7.20	$0.00	Disclosure SEC source: 0001562180-20-006681 · primarydocument.xml · derivative · entry 6 Morrison Briggs · CIK 0001654430 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,466 shares Expires 2025-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option is fully vested. Read SEC document
November 10, 2020 Filed Nov 12, 2020 22:55 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	SaleCommon Stock	17,466	$20.06	$350,312.07	Disclosure SEC source: 0001562180-20-006681 · primarydocument.xml · nonDerivative · entry 4 Morrison Briggs · CIK 0001654430 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,565 F3 · price: The sale prices ranged from $20.00 to $20.29. Read SEC document
November 10, 2020 Filed Nov 12, 2020 22:55 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	Exercise / conversionCommon Stock	17,466	$7.20	$125,755.20	Disclosure SEC source: 0001562180-20-006681 · primarydocument.xml · nonDerivative · entry 3 Morrison Briggs · CIK 0001654430 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,031 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 09, 2020 Filed Nov 12, 2020 22:55 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	Exercise / conversionStock Options (Right to buy) · Derivative	62,938	$0.00 Strike: $7.20	$0.00	Disclosure SEC source: 0001562180-20-006681 · primarydocument.xml · derivative · entry 5 Morrison Briggs · CIK 0001654430 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 62,938 shares Expires 2025-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option is fully vested. Read SEC document
November 09, 2020 Filed Nov 12, 2020 22:55 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	SaleCommon Stock	62,938	$20.04	$1,261,264.93	Disclosure SEC source: 0001562180-20-006681 · primarydocument.xml · nonDerivative · entry 2 Morrison Briggs · CIK 0001654430 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,565 F2 · price: The sale prices ranged from $20.00 to $20.21. Read SEC document
November 09, 2020 Filed Nov 12, 2020 22:55 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	Exercise / conversionCommon Stock	62,938	$7.20	$453,153.60	Disclosure SEC source: 0001562180-20-006681 · primarydocument.xml · nonDerivative · entry 1 Morrison Briggs · CIK 0001654430 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,503 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: The number of securities reported reflects the acquisition of 2,665 shares by the Reporting Person on 07/31/2020 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document
October 13, 2020 Filed Oct 16, 2020 00:10 UTC	Codiak BioSciences, Inc. CDAK · Entity 114958	GrantStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $15.00	$0.00	Disclosure SEC source: 0000899243-20-028415 · doc4.xml · derivative · entry 1 Morrison Briggs · CIK 0001654430 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2030-10-12 F1 · derivative.exercise_date: This option shall vest in full upon the earlier to occur of (i) October 13, 2021, and (ii) the next annual meeting of the Issuer's stockholders. Read SEC document
June 23, 2020 Filed Jun 25, 2020 21:57 UTC	Repare Therapeutics Inc. RPTX · Entity 68433	PurchaseCommon Shares	4,800	$20.00	$96,000.00	Disclosure SEC source: 0001209191-20-038972 · doc4.xml · nonDerivative · entry 1 Morrison Briggs · CIK 0001654430 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,800 Read SEC document
June 11, 2020 Filed Jun 15, 2020 21:45 UTC	NextCure, Inc. NXTC · Entity 7461	GrantStock Option (Right to Buy) · Derivative	14,250	$0.00 Strike: $24.13	$0.00	Disclosure SEC source: 0001123292-20-000883 · edgar.xml · derivative · entry 1 Morrison Briggs · CIK 0001654430 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,250 Underlying: Common Stock · 14,250 shares Expires 2030-06-10 F1 · derivative.exercise_date: The option vests in full on the earlier of June 11, 2021 and the date of the 2021 Annual Meeting of Stockholders. Read SEC document
June 03, 2020 Filed Jun 5, 2020 01:00 UTC	ARVINAS, INC. ARVN · Entity 5355	GrantStock Option (right to buy) · Derivative	12,000	$0.00 Strike: $33.57	$0.00	Disclosure SEC source: 0001209191-20-034588 · doc4.xml · derivative · entry 1 Morrison Briggs · CIK 0001654430 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2030-06-02 F1 · derivative.exercise_date: This option award was granted on June 3, 2020. The shares underlying the award shall vest in full on June 3, 2021 or, if earlier, the date of the first meeting of the board of directors of the Issuer held after the Issuer's next annual meeting of stockholders. Read SEC document
March 24, 2020 Filed Mar 25, 2020 20:45 UTC	ARVINAS, INC. ARVN · Entity 5355	PurchaseCommon Stock	2,500	$38.18	$95,450.00	Disclosure SEC source: 0001209191-20-021125 · doc4.xml · nonDerivative · entry 1 Morrison Briggs · CIK 0001654430 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,520 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $38.04 to $38.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within such range. Read SEC document
February 12, 2020 Filed Feb 14, 2020 21:36 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	GrantStock Option (Right to Buy) · Derivative	194,000	$0.00 Strike: $9.47	$0.00	Disclosure SEC source: 0001562180-20-001235 · primarydocument.xml · derivative · entry 1 Morrison Briggs · CIK 0001654430 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,000 Underlying: Common Stock · 194,000 shares Expires 2030-02-12 F1 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest monthly over a four-year period. Read SEC document
February 04, 2020 Filed Feb 5, 2020 21:07 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	PurchaseCommon Stock	12,500	$8.00	$100,000.00	Disclosure SEC source: 0001562180-20-000891 · primarydocument.xml · nonDerivative · entry 1 Morrison Briggs · CIK 0001654430 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,900 Read SEC document
October 10, 2019 Filed Oct 11, 2019 10:33 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	PurchaseCommon Stock	11,000	$5.40	$59,400.00	Disclosure SEC source: 0001562180-19-005140 · primarydocument.xml · nonDerivative · entry 1 Morrison Briggs · CIK 0001654430 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,400 Read SEC document
June 13, 2019 Filed Jun 18, 2019 00:21 UTC	NextCure, Inc. NXTC · Entity 7461	GrantStock Option (Right to Buy) · Derivative	22,000	$0.00 Strike: $15.57	$0.00	Disclosure SEC source: 0001123292-19-000889 · edgar.xml · derivative · entry 1 Morrison Briggs · CIK 0001654430 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2029-06-12 F1 · derivative.exercise_date: The option vests in three equal annual installments beginning on June 13, 2020. Read SEC document
May 23, 2019 Filed May 28, 2019 21:13 UTC	ARVINAS, INC. ARVN · Entity 5355	GrantStock Option (right to buy) · Derivative	12,923	$0.00 Strike: $22.06	$0.00	Disclosure SEC source: 0000899243-19-014881 · doc4.xml · derivative · entry 1 Morrison Briggs · CIK 0001654430 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,923 Underlying: Common Stock · 12,923 shares Expires 2029-05-22 F1 · derivative.exercise_date: This option award was granted on May 23, 2019. The shares underlying the award shall vest in full on May 23, 2020 or, if earlier, the date of the first meeting of the board of directors of the Issuer held after the Issuer's next annual meeting of stockholders. Read SEC document
May 13, 2019 Filed May 13, 2019 20:11 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	PurchaseCommon Stock	7,200	$7.29	$52,516.80	Disclosure SEC source: 0001562180-19-002780 · primarydocument.xml · nonDerivative · entry 2 Morrison Briggs · CIK 0001654430 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,400 Read SEC document
May 09, 2019 Filed May 13, 2019 20:11 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	PurchaseCommon Stock	13,200	$7.56	$99,726.00	Disclosure SEC source: 0001562180-19-002780 · primarydocument.xml · nonDerivative · entry 1 Morrison Briggs · CIK 0001654430 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,200 F1 · price: The purchase prices ranged from $7.50 to $7.60. Read SEC document
February 06, 2019 Filed Feb 8, 2019 21:28 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	GrantStock Option (Right to Buy) · Derivative	354,000	$0.00 Strike: $6.38	$0.00	Disclosure SEC source: 0001562180-19-000855 · primarydocument.xml · derivative · entry 1 Morrison Briggs · CIK 0001654430 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 354,000 Underlying: Common Stock · 354,000 shares Expires 2029-02-06 F1 · derivative.exercise_date: The securities awarded on 02/06/2019 were in the form of stock options issued pursuant to the Syndax Pharmaceuticals, Inc. 2015 Omnibus Incentive Plan. Options to purchase 177,000 shares of common stock shall vest in 48 successive equal monthly installments measured from 02/06/2019. Options to purchase 177,000 shares of common stock shall vest periodically upon the Issuer achieving certain milestones. Read SEC document
September 26, 2018 Filed Sep 29, 2018 00:38 UTC	ARVINAS, INC. ARVN · Entity 5355	GrantStock Option (right to buy) · Derivative	32,870	$0.00 Strike: $16.00	$0.00	Disclosure SEC source: 0000899243-18-025547 · doc4.xml · derivative · entry 2 Morrison Briggs · CIK 0001654430 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,870 Underlying: Common Stock · 32,870 shares Expires 2028-09-25 F2 · derivative.exercise_date: This option award was granted on September 26, 2018. 1/12 of the shares underlying the award vested as of June 28, 2018, with the reminder of the shares vesting in equal quarterly installments following June 28, 2018 through March 28, 2021. Read SEC document
September 26, 2018 Filed Sep 29, 2018 00:38 UTC	ARVINAS, INC. ARVN · Entity 5355	GrantStock Option (right to buy) · Derivative	6,960	$0.00 Strike: $16.00	$0.00	Disclosure SEC source: 0000899243-18-025547 · doc4.xml · derivative · entry 1 Morrison Briggs · CIK 0001654430 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,960 Underlying: Common Stock · 6,960 shares Expires 2028-09-25 F1 · derivative.exercise_date: This option award was granted on September 26, 2018. 1/4 of the shares underlying the award vested as of September 1, 2017, with the remainder of the shares vesting in equal monthly installments following September 1, 2017 through September 1, 2020. Read SEC document
March 01, 2018 Filed Mar 5, 2018 21:04 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	GrantStock Option (Right to Buy) · Derivative	200,000	$0.00 Strike: $9.40	$0.00	Disclosure SEC source: 0001562180-18-001427 · primarydocument.xml · derivative · entry 1 Morrison Briggs · CIK 0001654430 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2028-03-01 F1 · derivative.exercise_date: The stock option will vest in 48 successive equal monthly installments measured from February 8, 2018. Read SEC document
February 06, 2017 Filed Feb 8, 2017 19:13 UTC	Syndax Pharmaceuticals Inc SNDX · Entity 4578	GrantStock Option (Right to Buy) · Derivative	160,000	$0.00 Strike: $8.77	$0.00	Disclosure SEC source: 0001562180-17-000569 · primarydocument.xml · derivative · entry 1 Morrison Briggs · CIK 0001654430 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2027-02-06 F1 · derivative.exercise_date: The stock option will vest in 48 successive equal monthly installments measured from February 6, 2017. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.